Partnerships
target your drug to the lung with unprecedented accuracy and efficiency
Collaborators and licensors can now access the same market-equivalent devices that are fundamental to the development of our own portfolio of inhaled drug/device combination products for critical care.
We enable partners to develop cutting-edge inhaled therapies, and may also consider in-licensing the most promising candidates for further development at our own expense.
Drug delivery partnerships
Aerogen Pharma’s proprietary PDAP delivery system offers unmatched performance and user convenience for aerosol delivery to patients via life support ventilators and non-invasive respiratory equipment. We welcome development partnerships with innovator companies seeking to access this platform, including customized device iterations, for delivery of NCEs, NBEs and certain categories of generic therapeutics. Aerogen Pharma technology can ensure that your drug candidate is delivered to the lungs of your target patient population with unparalleled accuracy and efficiency, reducing dose-to-dose and inter-patient variability and reducing consumption and wastage of expensive APIs. We offer flexible terms of business, including options to minimize investment outlay during clinical development.
Inhaled drug development
Aerogen Pharma has specialist knowledge and capabilities pertaining to the development of liquid formulations for nebulised delivery. As part of a development program targeting patients in a hospital setting, we offer consulting and advisory services in the areas of aerosol delivery with assisted ventilation and respiratory care, and the regulatory, CMC and clinical aspects of inhaled drug development. We can also conduct as a service the mandated characterization testing necessary to support regulatory filings and clinical campaigns for liquid aerosol formulations across major global markets.
Commercial hospital nebuliser systems
Our sister company Aerogen Limited, also part of the Aerogen Group, is the global market leader in high performance aerosol drug delivery, reaching over 16 million patients in 75 different countries with an international reputation for premium product quality, performance and reliability. These widely approved devices can provide potential Aerogen Pharma development partners with convenient, rapidly deployable tools for preclinical and early clinical investigation in preparation for development with the more advanced Aerogen Pharma system for acute and critical care applications.Nuance Pharma
Nuance is a clinical-stage biopharma company with a late-stage clinical pipeline and a portfolio of commercialized assets across respiratory, emergency care, iron deficiency anemia and pain management indications. With the mission to address critical unmet needs in Asia Pacific, Nuance deploys the Dual Wheel model that develops a leading innovative pipeline, while maintaining a self-sustainable commercial operation in China and Asia. For more information, please visit https://www.nuancepharma.com.
Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory.
Get in touch
To engage us on partnerships, please provide
a few details below and we’ll have the right
Aerogen Pharma representative get in touch.